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Abstract
Alport syndrome (AS) is a familial glomerular disorder resulting from mutations in the genes
encoding several members of the type IV collagen protein family. Despite advances in molecular
genetics, renal biopsy remains an important initial diagnostic tool. Histological diagnosis is challen-
ging as features may be non-specific, particularly early in the disease course and in females with
X-linked disease. We present three families for whom there was difficulty in correctly diagnosing
AS or thin basement membrane nephropathy as a result of misinterpretation of non-specific and
incomplete histology. We highlight the importance of electron microscopy and immunofluores-
cence in improving diagnostic yield and also the hazard of interpreting a descriptive histological
term as a diagnostic label. Molecular genetic testing allows a definitive diagnosis to be made in
index patients and at-risk family members.
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Introduction
Alport syndrome (AS) is an inherited disease that results
in progressive glomerular damage, often in association
with sensorineural hearing loss and ocular disease. It is
caused by a number of genetic mutations affecting type
IV collagen, a constituent of the glomerular basement
membrane, cochlea and eye [1–3]. Type IV collagen is a
heterotrimeric extracellular protein that forms an impor-
tant part of the glomerular basement membrane. In the
adult kidney this complex is composed of subunits
encoded by the genes COL4A3 and COL4A4 (which are
situated on chromosome 2) and COL4A5 which lies on the
X chromosome. AS may be caused by homozygous or
compound heterozygous mutations of COL4A3 or COL4A4,
or by hemizygosity for a single defective COL4A5 allele in
males [4]. This explains the autosomal-recessive and
X-linked modes of inheritance that are seen in clinical
practice. Heterozygosity for a pathogenic mutation of any
of these genes can be associated with microscopic hae-
maturia, thinning of the glomerular basement mem-
branes and a low, but non-negligible, risk of renal
impairment. Known heterozygous carriers of AS therefore
require long-termmedical follow-up [4].
Advances in molecular genetics, including the discovery
of the COL4A family of genes, have led to the use of genetic
testing in confirming a diagnosis of AS. Detection of
mutations in COL4A5 gene in males with X-linked AS can be
up to 95% using contemporary techniques [5]. However, in
patients with suggestive clinical features and or a relevant
family history, renal biopsy remains the primary initial diag-
nostic tool used to identify patients with AS [4].
Diagnosing AS histologically can be challenging because
findings on light microscopy are often non-specific. Classi-
cally, patients exhibit increased glomerular cellularity and
an interstitial infiltrate containing lipid-laden foam cells,
which is a bad prognostic marker [6]. However, patients
may also exhibit glomerulosclerosis and mesangial
changes which can be misleading. Hallmark ultrastructural
lesions such as thinning, thickening and longitudinal split-
ting of the glomerular basement membrane strongly
suggest type IV collagen-associated disease but cannot
always distinguish AS from thin glomerular basement ne-
phropathy (TBMN) [7]. In addition, electron microscopy
(EM) of glomeruli is not always available. Here we present
three families in which incomplete or incorrectly inter-
preted clinical and histological data led to diagnostic inac-
curacies that were resolved by genetic testing.
Case reports
Family 1
A 26-year-old man presented with hypertension, haema-
turia, nephrotic-range proteinuria and a normal GFR. Of
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note, his past medical history included sensorineural deaf-
ness and his mother also had a history of chronic kidney
disease (Figure 1A).
He underwent a renal biopsy which revealed on light
microscopy features consistent with focal segmental
glomerulosclerosis (FSGS) with hypertensive changes.
However electron microscopy (EM) examination of the
biopsy revealed splitting of the glomerular basement
membrane, consistent with AS (Figure 1B).
His mother had reached end-stage renal disease (ESRD)
at 32 years of age and had undergone a successful renal
transplant. She carried the diagnostic label of membrano-
proliferative glomerulonephritis (MPGN). A review of her
native renal biopsy revealed the changes were limited to
mild mesangial proliferation on light microscopy. Unfortu-
nately there were no glomeruli in EM or immunofluores-
cence (IMF) specimens to allow elaboration of these
findings. These features on light microscopy had, over
time, been mistranslated into a diagnostic label of MPGN.
Genetic testing confirmed that both mother and son
had a novel c.685A>T, p.Lys229X mutation in the COL4A5
gene (Figure 1C), which is predicted to be pathogenic, con-
firming X-linked AS.
The proband developed progressive renal impairment
associated with persistent proteinuria. Had his mother’s
initial diagnosis been accurate, his renal biopsy could have
been avoided and earlier detection and management of
his hypertension and proteinuria may have slowed the
rate of decline of his renal function.
Family 2
A 25-year-old man presented in 1984 with intermittent
macroscopic haematuria, hypertension, normal renal
function (creatinine clearance 154 mL/min) and proteinur-
ia (0.2 g/24 h). His renal function has remained stable over
29 years of follow-up (serum creatinine 93 µmol/L aged
54 years). A family history revealed two brothers who pro-
gressed to ESRD aged 46 and 57, as well as a sister and
mother affected with chronic kidney disease in whom no
histological or clinical diagnosis was available (Figure 1A).
The proband underwent renal biopsy in 1985 which
showed possible mesangial expansion with no significant
immunoperoxidase staining, and was interpreted as ‘poss-
ible MPGN’. His half-brother was biopsied in 1987, showing
glomerulosclerosis associated with a proliferative glomer-
ulonephritis. His elder brother was biopsied in 1996 when
he too had advanced renal impairment (serum creatinine
390 µmol/L), demonstrating advanced glomerulosclerosis
with mesangial expansion but negative immunofluores-
cence. There were no EM reports or photos from the 1985
biopsy, and the 1996 biopsy had no glomeruli in the tissue
submitted for EM.
DNA analysis using whole exome sequencing confirmed
that the proband carried the c.G3508A mutation in COL4A5
(Figure 1C), which is known to cause X-linked AS [8]. This
mutation was also found in his half-brother on dialysis but
not in his unaffected brothers. The proband’s affected
brother had died 7 years prior to the identification of this
mutation. We were however able to perform PCR on DNA
extracted from serum stored at the transplant unit and
confirmed that he too had the identical mutation.
There was no family history of deafness; however, sub-
sequent auditory assessment in the index case revealed
mild left-sided presbyacusis with more marked hearing
loss down to 60 dB on the right. There were also no
characteristic lens abnormalities; however, there were
peripheral retinal changes that might be associated
with AS.
Family 3
A 47-year-old woman presented with haematuria, hyper-
tension, abnormal renal function (serum creatinine 114
µmol/L), proteinuria and mild high-tone sensorineural
hearing loss. A family history revealed a sister with
hearing loss and microscopic haematuria, a nephew with
microscopic haematuria and two daughters with micro-
scopic haematuria, suggesting a dominant inheritance
pattern (Figure 1A). A renal biopsy of the proband showed
mild mesangial proliferative changes (Figure 1B) but no
specific diagnostic features.
The biopsy was insufficient to allow EM analysis. The
association of high-frequency hearing loss and haematur-
ia raised the suspicion of a hereditary nephritis.
DNA analysis confirmed that the proband, her sister and
two of her three daughters were heterozygotes for a novel
pathogenic mutation of the COL4A3 gene (c.1148G.A,
p.Gly395Glu) (Figure 1C). This indicates a diagnosis of
autosomal-dominant TBMN. This variant is predicted to in-
terrupt the GLY-X-Y repeat structure of the collagenous
domain of the alpha-3 chain. Missense changes within this
region have been previously reported in AS patients [9].
These family members now are now under regular renal
follow-up and fortunately have only microscopic haematur-
ia with normal renal function and blood pressure at present.
Discussion
The difficulty in securing a diagnosis of AS from histological
analysis of renal biopsy specimens has been described in a
Chinese case–control study by Yao et al. [10]. The authors re-
vealed that mesangial proliferative glomerulonephritis was
the most common misdiagnosis in male patients with
X-linked AS and that FSGSwas themost commonmisdiagno-
sis in female patients with X-linked AS. It was acknowledged
that often EM and collagen protein immunofluorescence
studies were not available or had not been performed on
biopsy samples from those misdiagnosed.
Females heterozygous for mutations in COL4A5 that
cause X-linked AS have a variable phenotype, with ∼15%
eventually developing ESRD, at a median age of 49 years—
a risk broadly similar to that seen in individuals with AD
TBMN who are heterozygous for pathogenic autosomal
COL4A3 and COL4A4 mutations [11, 12]. This is in marked
contrast to males with X-linked AS (who are hemizygous
for pathogenic COL4A5 mutations) or individuals homozy-
gous or compound heterozygous for autosomal COL4A3 or
COL4A4 mutations, in whom the risk of ESRD is >90%, with
median age of onset 25 years or less [13, 14].
Analysis of the pedigree of Family 1 presented here
suggests that the proband’s mother is likely to have had a
de novo mutation. Both of these factors may have con-
spired to make AS a less likely clinical differential at the
time of her original biopsy. Coupled with the non-specific
findings on histology and in the absence of information
from EM and IMF studies, her misdiagnosis seems almost
inevitable. However, we note that a review of this biopsy
concluded that although some glomeruli exhibited me-
sangial proliferative changes, these were not sufficient to
warrant a histological diagnosis of MPGN. This case de-
monstrates that misinterpretation and mistranslation of a
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descriptive into a diagnostic term can be a crucial flaw
leading to misdiagnosis. It is conceivable that a proportion
of misdiagnoses identified by Yao et al. may have been
related to a similar error in interpretation.
In Family 2, the relatively mild disease manifestations in
the proband, coupled with insufficient or unavailable
biopsy material for electron microscopic examination, had
also led to the histological appearances of mesangial pro-
liferation being translated into a diagnostic label of poss-
ible MPGN. Molecular testing allowed the correct diagnosis
of X-linked AS to be made.
In Family 3 an original clinical diagnosis of probable
X-linked AS was revised by the identification of a patho-
genic heterozygous autosomal COL4A3 mutation co-
segregating with disease. This molecular diagnosis has
had significant implications for the family, since it is now
clear that male offspring of affected female members of
this family bear a 50% risk of inheriting TBMN and are not
at risk of the more severe X-linked AS.
Extra-renal features of AS, including sensorineural deaf-
ness, anterior lenticonus and dot and fleck retinopathy can
provide important diagnostic clues. However, as illustrated
here and previously, these features are not always present
even when there is advanced renal disease [15, 16]. In
addition, sensorineural hearing impairment is sometimes
seen in TBMN and other disorders that cause kidney failure,
such as autosomal-dominant MYH9-associated diseases,
including Fechtner and Epstein syndromes [17] and bran-
chio-oto-renal syndrome, which is caused by heterozygous
mutations of the EYA1, SIX1 and SIX5 genes [18]. While
Fig. 1. Family structure, genetic analysis and histological features. (A) Pedigree structure of Family 1, 2 and 3. Probands are arrowed. Squares represent
males, circles represent females. Affected individuals are shaded. CKD, chronic kidney disease; ESRD, end-stage renal disease. (B) Left, renal biopsy EM
image from proband of Family 1 showing thinning of the glomerular basement membrane. Right, renal biopsy under light microscopy (silver stain) of
proband from Family 3 revealed only very mild mesangial proliferative changes. (C) Sequence chromatograms of COL4A5 (Family 1 and 2) and COL4A3
(Family 3) in affected patients with wild-type control. Nucleotides are shown and corresponding amino acids are numbered. Sequence variants are
arrowed.
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extra-renal features may be helpful in suggesting a likely
clinical differential diagnosis, they cannot be relied upon to
make a firm diagnosis in familial kidney diseases.
In order to accurately identify families with AS, care
must be taken by nephrologists in interpreting non-specific
histological terminology, and vigilance in separating de-
scriptive histological terms from diagnostic labels is
needed. Furthermore, it is vital to ensure EM and ideally IF
for collagen proteins are available and reviewed in patients
with unexplained haematuria even in the absence of a
family history. Light microscopic appearances of prolifera-
tive glomerulonephritis can also be caused by non-
immune-mediated diseases, including type IV collagen
abnormalities, which should feature in the differential di-
agnosis unless there is good evidence of immune-complex
disease on clinical, serological, immunostaining or ultra-
structural grounds.
Although not 100% sensitive, genetic testing can provide
a definitive means of making a diagnosis of AS in the vast
majority of cases and (in the absence of male-to-male
transmission elsewhere in the family) is the most reliable
way to distinguish females who are carriers of X-linked AS
from those with heterozygous COL4A3 or COL4A4
mutations. This distinction may be especially important in
women planning to start a family, since in the former situ-
ation male, but not female, offspring will have a significant
risk of ESRD in childhood and this knowledge may inform a
decision to undergo prenatal testing. Once a genetic diag-
nosis has beenmade, this can enable screening of sympto-
matic or at-risk family members and may obviate the need
for a kidney biopsy in some circumstances.
In addition to diagnostic information, uncovering the
genetic change in a patient with AS may provide additional
prognostic information, since early stop codons, frameshift
mutations, large deletions and rearrangements have been
associated with earlier onset renal failure and deafness
than missense mutations and these more destructive
genetic alterations are possibly more likely to be associated
with de novo antiglomerular basement membrane disease
following transplantation [13]. Together these cases illus-
trate the diagnostic power that the application of molecu-
lar genetics to clinical practice can bring to the diagnosis
of patients with kidney disease.
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